Podcasts about clinical trials

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt's disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio's mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio's clinical trials. Learn more here: www.splice.bio/clinical Or send an email to: Clinicaltrials@splice.bio #SpliceBio #genetherapy #clinicaltrials

Delays in diagnosing and treating pulmonary hypertension (PH) can have life-altering consequences. In this episode, Dr. Kari Gillmeyer, discusses her groundbreaking study on PH care networks. She explores why so many patients experience delays, how geography and provider access play a role, and what can be done to improve timeliness of care. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @VABostonHC @The_BMC @JNJInnovMed

As clinical research becomes increasingly digital, the legal and compliance landscape is shifting. Hal Porter, Director of Consulting Services, Clearwater, speaks with Dianne Bourque, Partner, Holland & Knight LLP, about the legal, regulatory, and ethical considerations when clinical trial data is compromised. They discuss issues related to regulatory frameworks and legal obligations, risk exposure and liability, impacts of a breach that go beyond privacy, cross border data and transfer risks, and mitigating the risk and fallout of data breaches in clinical trials. Sponsored by Clearwater.Watch this episode: https://youtu.be/XwtZXXGmLx4Learn more about Clearwater: https://clearwatersecurity.com/ Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

The University of Galway is leading three new projects that aim to make medical treatments safer, faster and more effective after researchers secured the support of one of Europe's most prestigious funding programmes. The awards were made by the European Commission's Marie Sklodowska Curie Actions-Doctoral Network programme (MSCA DN), as part of Horizon Europe 2020. The programme supports researchers to become future leaders while investing in the University of Galway projects to improve lives and pave the way for better, more affordable healthcare. The network also provides training to make the researchers more creative, entrepreneurial and innovative, boosting their employability in the long term. One University of Galway project has an emphasis on sustainability and a move away from animal testing for brain disease; a second is looking at cardiovascular issues, specifically around improving heart stent durability and longevity; and a third seeks to advance equity, diversity and inclusion in clinical trials. Professor Fidelma Dunne, Director of the Institute for Clinical Trials at the University of Galway, said: "These projects show how research can make a real difference in people's lives. University of Galway is proud to be leading the way in creating smarter, safer, and more sustainable healthcare solutions." Professor Ted Vaughan, Interim Director of the Institute for Health Discovery and Innovation at the University of Galway, said: "These projects exemplify the mission of our new Institute - to accelerate fundamental and applied understanding of disease and enable disruptive solutions to health-based challenges. By combining cutting-edge science with collaborative training, we are not only advancing medical technologies but also shaping the next generation of research leaders. This investment from the European Commission underscores the importance of innovation that is ethical, inclusive, and focused on improving patient outcomes across society." The University of Galway projects funded by the Marie Sklodowska Curie Actions-Doctoral Network are: Dr Mihai Lomora leads the €4.2 million CerebroMachinesTrain Doctoral Network research project - Smarter Drug Delivery for Brain Diseases. Using advanced 3D brain models that mimic real brain tissue, the project will test tiny machines which are being developed to bring medicine exactly where it is needed. It avoids animal testing, making research faster, more ethical, and more accurate. Dr Lomora is a Lecturer and Principal Investigator in Bio(material) Chemistry at the University's School of Biological and Chemical Sciences in the College of Science and Engineering and a Funded Investigator at CÚRAM - the Research Ireland Centre for Medical Devices. This network project involves 14 partners from eight countries, including the US. Four PhD students will be supported through the project at the University of Galway. Dr William Ronan leads the €2.71 million MEDALLOY research project - Stronger, Safer Materials for Life-Saving Devices. It focuses on making materials used in minimally invasive medical devices - like stents and heart valve supports - stronger and longer lasting. Dr Ronan is a Lecturer and Principal Investigator in Biomedical Engineering at the University's College of Science and Engineering. The project includes partners from six countries - the US, Ireland, Italy, Germany, Czechia and Sweden. It will train nine PhD students, who will spend at least half of their time working directly in industry, earning hands-on skills ranging from material science to patient care. Dr Eimear Morrissey leads the €4.4 million EDICT research project - Advancing Equity, Diversity and Inclusion in Clinical Trials. It is a research and training network led by the Health Research Board-Trials Methodology Research Network, based at the University of Galway, which seeks to include older adults, ethnic minorities, people with disabilities, or those from lower-income backgrounds in clinica...

Health care executive Shelli Pavone discusses her article "Why retail pharmacies are the future of diverse clinical trials," highlighting the urgent need to improve representation in clinical research. Shelli explains how barriers like mistrust, cost, and lack of access have historically excluded women and minority populations, leading to less effective treatments and persistent health disparities. She describes how leveraging retail pharmacies—trusted, accessible community hubs—can decentralize trials, expand recruitment, and boost retention. Listeners will gain practical insights on how pharmacies' existing infrastructure can be adapted for clinical research, why inclusivity matters for health outcomes, and how patient-centered innovation can reshape the future of medicine. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Carole Bakhos joins us for an update on where we stand with the clinical trial. There are a few spots open now so take a listen to see if you are eligible to get involved. A must listen for all of our families!

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the importance of taking reasonable precautions for health and safety. He recounts his experience at a recent Jacksonville Jaguars football game, which was delayed out of an abundance of caution due to a lightning storm. Dr. Koren explains that although the delay was annoying and disruptive, safety must come first. The two relate this to health-related precautions, such as managing cholesterol and obesity, as well as the rigorous safety measures in clinical trials.   Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Tolaney focuses on advancing breast cancer treatment through innovative clinical research. She has been instrumental in developing novel therapies and leading key clinical trials, particularly for early-stage HER2-positive breast cancer.     Timestamps   00:09 – Introduction  01:12 – What is HER2-positive breast cancer?  03:00 – Key trials Tolaney has led  07:16 – Antibody-drug conjugates  12:00 - Breast Oncology Guidelines  14:51 – Treatment optimisation   18:27 – Equity in healthcare  21:10 – Mentoring the next generation of oncologists  22:52 – Tolaney's wishes for healthcare 

"In the history of science, innovative concepts occasionally arise from sudden left-field inspiration." Here we make sure everyone is up to speed on the types of CRISPR inhibition for FSHD and FSHD epigenetics s that we are all ready to evaluate the preclinical data supporting the Epicrispr Biotechnology EPI321 clinical trial.

"But did you bleed him? - Aesculapius says that bleeding is not a cure. It is only a way of proving that you are a physician at the expense of your patient." Finally, we discuss the EPI-321 epigenetic editing phase I/II clinical trial design and its potential for answering key questions necessary for going to phase III and for providing benefit to participants and patients.

Nutritionist Leyla Muedin discusses recent advancements in the detection and prevention of Alzheimer's disease. Topics include the new FDA-approved Lumipulse blood test, the role of a ketogenic diet in improving mitochondrial health, and the significance of lifestyle changes such as social and cognitive activities. The episode also highlights promising research from the University of California Irvine on using natural compounds like nicotinamide and EGCG to rejuvenate aging brain cells and address the buildup of Alzheimer's-associated proteins. Leyla also provides insights into the difference between Alzheimer's and general dementia and emphasizes the importance of accurate diagnosis and appropriate treatments.

To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts More people with Parkinson's are impacted by the LRRK2 (often pronounced "Lark two") gene than you might expect. The NEULARK study is a phase II clinical trial designed to investigate whether a new treatment being researched, NEU-411, can slow disease progression and improve quality of life for people with Parkinson's disease. NEU-411 is an oral medication designed to inhibit overactivity of the LRRK2 gene. In this episode of The Parkinson's Podcast, we talk with Dr. Fatta Nahab about the NEULARK study. This episode is sponsored by Neuron23, who is also sponsoring the NEULARK study. Our guest, Dr. Nahab, is Vice President of Clinical and Digital Development for Neuron23.  For more information about the NEULARK trial please visit:  https://parkinsonsresearchlrrk2.com/  or  https://clinicaltrials.gov/study/NCT06680830   Season: 6 Episode: 19

In today's episode, we passed the mic to Tara E. Seery, MD, who moderated an OncLive Insights discussion on the future of the pancreatic cancer treatment paradigm. Rounding out the discussion with additional expert perspectives were Paul E. Oberstein, MD, and Priyadarshini Pathak, MBBS. Seery is a medical oncologist at the Hoag Family Cancer Institute in Newport Beach, California. Oberstein is an associate professor in the Department of Medicine at the New York University (NYU) Grossman School of Medicine; as well as the director of the Gastrointestinal Medical Oncology Program, the assistant director of the Pancreatic Cancer Center, and the service chief of the Gastrointestinal Medical Oncology Program at NYU Langone's Perlmutter Cancer Center. Pathak is an assistant in medicine at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School in Boston.  In this exclusive conversation, Drs Seery, Oberstein, and Pathak highlighted key data from the phase 3 NAPOLI 3 trial (NCT04083235) of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, and oxaliplatin) vs nab-paclitaxel (Abraxane) and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma; the toxicity profiles of NALIRIFOX and FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin); real-world data with these regimens, and more. 

Psychedelics like LSD, psilocybin, and ketamine are being tested to treat disorders like PTSD and anxiety.

In this episode of Longevity by Design, Dr. Gil Blander welcomes Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging. Eric discusses the science behind therapeutic plasma exchange (TPE) and its potential to slow biological aging in humans. The conversation explores findings from a recent clinical trial, including measurable age reversal using epigenetic clocks.Eric explains how removing and replacing plasma can dilute pro-aging factors in the blood, a concept inspired by earlier animal studies on parabiosis. He also describes why rigorous, placebo-controlled human trials are crucial for validating longevity interventions and distinguishing the field from hype-driven wellness trends.The episode also highlights how omics data, such as metabolomics and proteomics, are shaping a new era of precision aging research. Eric emphasizes the value of lifestyle interventions as a foundation and sees future opportunities in combining TPE with personalized strategies to extend healthspan.  Guest-at-a-Glance

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

Meet Sarah Kennedy, CEO and founder of Calocurb, a revolutionary weight management product born from 15 years and $30 million of New Zealand government-backed science. If you've ever struggled with your relationship to food, including overeating, yo-yo dieting, or the constant battle with your willpower, this conversation will give you a refreshing new perspective.We explore the fascinating science of appetite suppression, from the evolutionary role of hunger and the “hindbrain” to the discovery that bitter compounds in hops can naturally stimulate GLP-1 and other satiety hormones. We also get into the history of how Scottish highlanders and Kalahari tribes used bitter plants for appetite control, how modern agriculture stripped bitters from our diet, and why restoring this missing piece could be a game-changer. If you've been looking for a natural, science-backed way to modernize your eating habits and find peace with food, this episode is for you. Visit calocurb.com/lukestorey and use code LUKE10 for 10% off your first order.DISCLAIMER: This podcast is for educational purposes only and not intended for diagnosing or treating illnesses. The hosts disclaim responsibility for any adverse effects from using the information presented. Consult your healthcare provider before using referenced products. This podcast may include paid endorsements.THIS SHOW IS BROUGHT TO YOU BY:KORRECT | Go to korrectlife.com/luke and use the code LUKE to get 15% off.FLFE | Try Focused Life-Force Energy for FREE for 15 days at lukestorey.com/flfe.SUNLIGHTEN | Save up to $600 when you go to lukestorey.com/sunlighten and use code LUKESTOREY in the pricing form.JUST THRIVE | Head to lukestorey.com/justthrive and use code LUKE20 to save 20%.MORE ABOUT THIS EPISODE:(00:00:00) The Science Behind Appetite Suppression(00:21:45) Clinical Trials, Hunger Science, & Alternatives to Injectables(00:38:37) Bitters, Dosing Protocols, & What's Actually in Calocurb(00:57:27) GLP-1 Side Effects, Vagus Nerve, & Fasting Use Cases(01:09:34) Sarah's Journey, Innovation, & Life LessonsResources:• Website: calocurb.com • Instagram: instagram.com/calocurb • Facebook: facebook.com/calocurbGLOBAL • X: x.com/Calocurb • TikTok: tiktok.com/@calocurb • YouTube: youtube.com/@calocurb • Shop all our merch designs at lukestoreymerch.com• Check out Gilded By Luke Storey:

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Michael Koren joins Kevin Geddings to report live from Madrid on new developments being presented at the European Society of Cardiology meeting. This medical gathering, now the world's largest, is a showcase of developments in heart health and medicine. Dr. Koren notes excitement about progress in treating a genetic condition, lipoprotein(a), which raises cholesterol independently from diet and exercise. He notes that progress in this field is showing promise and that those with a family history of heart disease should have their lipoprotein(a) checked!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Living with MS means living with uncertainty, possible physical disability or cognitive dysfunction, bouts of crushing fatigue, mood changes, and let's not forget the very real irritation of well-meaning people telling you how healthy you look. Just processing the world around you can feel challenging. In this episode, psychologist Dr. Miriam Franco joins me to discuss how developing a growth mindset can make all the difference in how you experience your MS journey.   We're also sharing a real-world example of how the drastic cuts in federal funding are already impacting MS care. We'll tell you about the first country in the world to approve Tolebrutinib, a new disease-modifying therapy for nonrelapsing secondary progressive MS. And we'll explain why people are particularly excited about this medication. We'll share details about the MS Clinical Imaging and Data Resource that's been launched by the International Progressive MS Alliance. We'll tell you how and where to catch the MS Standup Comedy Benefit next Monday in New York. And we're reminding you about your opportunity to impact future MS therapies by helping the FDA better understand what living with MS is really like. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Developing a growth mindset  :22 How those federal research funding cuts are impacting MS patient care  1:30 United Arab Emirates becomes the first country in the world to approve Tolebrutinib for nonrelapsing secondary progressive MS  5:05 The International Progressive MS Alliance launches an MS Clinical Imaging and Data Resource open to the MS research community   8:32 The MS Standup Comedy Benefit takes place next Monday in New York  10:15 Add your voice and participate in the Shaping Tomorrow Together initiative  11:04 Dr. Miriam Franco discusses what it means to have a growth mindset when you're living with MS   14:50 Share this episode  34:11 Next week's episode   34:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/418 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 VIDEO: Dr. Robert Fox, Principal Investigator in the Phase 3 Clinical Trial for Tolebrutinib and Secondary Progressive MS https://youtu.be/tJQ93qdlXrU?si=S5jREy5ixVcE7ol- VIDEO: Dr. Jiwon Oh, Principal Investigator in the Phase 3 Clinical Trial for Tolebrutinib and Relapsing-Remitting MS https://youtu.be/zcBmAHRTotA?si=n86KRjB9Xt9sdZMg The International Progressive MS Alliance Clinical Imaging and Data Resource https://progressivemsalliance.org/ms-clinical-and-imaging-data-resource ATTEND: MS Stand-Up Comedy Benefit  https://msstandup.org Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 418 Guest: Dr. Miriam Franco Privacy Policy

Join us as we delve into the evolving landscape of clinical trials in Latin America with Julio G. Martinez-Clark, CEO of BioAccess. Discover how his company is pioneering pathways for medtech innovators and shaping the future of medical device innovation in emerging markets.   Bioaccess® is a trailblazing company that's helped over 100 Medtech innovators navigate global clinical trials, and he currently serves as Ambassador of International Accrediting Organization for Clinical Research in the Americas. With a career that spans healthcare infrastructure, telecommunications, and regulatory strategy, Julio is a leading voice in the field of medical device innovation in emerging markets.   From his early days at Johns Hopkins Hospital to his current role in shaping ethical and efficient trial systems across Latin America, Julio's mission is clear: to expand access to high-quality research for patients and sponsors alike. He's also the host of the Global Trial Accelerators™ podcast, where he dives into trends in Medtech, Biopharma, Radiopharma and clinical trial innovation.   We unpack what makes Latin America a strategic region for clinical trials, especially for rare diseases, and explore how improving trial access can speed innovation, and change lives.   Episode Discussion Topics:    Introduction to Julio G. Martinez-Clark and his role at BioAccess. The clinical trial landscape in Latin America and its strategic importance. Julio's career journey from Johns Hopkins Hospital to BioAccess. The impact of cultural competence and community engagement on clinical trials. Challenges and solutions for conducting clinical trials during the pandemic. The role of artificial intelligence and digital tools in clinical trials. The future of clinical research in Latin America, including radiopharmaceuticals and theranostics. The importance of international standards and certifications for clinical research sites. Success stories and innovative approaches in clinical trials. Julio's podcast, Global Trial Innovators, and its focus on industry education. During the episode a blog post on bioaccess' website was referenced that highlights academic papers that talk about the higher recruitment and retention rates in Latin America, here it is: https://www.bioaccessla.com/blog/the-latin-american-advantage-why-clinical-trial-recruitment-and-retention-outpace-the-us-and-europe   Connect With Us:   Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

Send us a textIn this episode of the Life Science Success Podcast my guest is Victoria Donovan. Victoria is the Founder and CEO of Clinically Media, an award-winning agency that is transforming patient recruitment and retention strategies in clinical research.00:00 Introduction to Life Science Success Podcast00:38 Meet Victoria Donovan: Founder and CEO of Clinically Media01:34 Victoria's Journey into Life Sciences03:12 The Birth and Growth of Clinically Media05:03 Clinically Media's Mission and Vision08:46 Innovative Approaches in Patient Recruitment11:59 Challenges and Future of Patient Recruitment23:45 Leadership and Personal Insights from Victoria Donovan32:34 Conclusion and Final Thoughts

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Laura Brinker to the podcast! Laura Brinker, DPM, was previously a Vice President of Clinical Affairs at Paragon 28, where she drove innovation in foot and ankle surgical solutions. She now has a consulting firm to address advancements of medical devices, regulatory compliance, and clinical trials. With a background in Mechanical Engineering from Purdue and a DPM from Temple University, she completed her residency at the University of Louisville/Jewish Hospital. Dr. Brinker has combined private practice experience, clinical research, and engineering expertise to advance podiatric surgery and medical device development. Enjoy this entrepreneurial discussion with a young leader in our profession!

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

As global regulatory expectations evolve, biotech sponsors face growing pressure to make smarter, earlier decisions about where and how to run their trials. In this episode, Novotech experts Renita Hite (Director of Regulatory Affairs, Drug Development Consulting) and Scott Schliebner (Global Head of Drug Development Consulting) join moderator Meredith Landry to discuss how early-stage sponsors can adapt to shifting FDA initiatives, accelerated global pathways, and increasing demands for regulatory flexibility. They explore: How new FDA initiatives—like AI-driven reviews, user fee changes, and the National Priority Voucher—are reshaping IND strategy Why sponsors should design trials with global data packages in mind from day one Accelerated and early access pathways that can speed startup and market entry How CROs are evolving to help sponsors prioritize markets and build regulatory flexibility If you're planning trials for 2025 and beyond, this conversation will help you prepare for what's next—and position your program for long-term success. About This Episode This episode is the final installment (4 of 4) in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Catch up on earlier episodes: [Part 1: Navigating Regulatory Changes & Market Dynamics] [Part 2: Navigating Regulatory & Market Shifts] [Part 3: Navigating Regulatory Changes & Market Dynamics]

Small cell lung cancer was once considered one of the most challenging diagnoses in oncology. But today, groundbreaking treatments are transforming patient outcomes and rewriting survival stories. Discover how immunotherapy, T-cell engagers, CAR T-cell therapy, and antibody drug conjugates are moving from clinical trials to standard care, offering patients years of disease control and genuine hope for the future. Featuring insights from Dr. Jacob Sands, thoracic oncologist at Dana-Farber Cancer Institute, and inspiring patient advocate Wendy Brooks, who shares her powerful journey from early detection through cutting-edge clinical trials, proving that advocacy and hope can change everything. Guests: Dr. Jacob Sands, Oncologist, Dana-Farber Cancer Institute Courtney Mantz, Program Manager II, SCLC Program, Dr. Sands' Assistant. Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology Wendy Brooks, Patient Advocate Show Notes | Transcript | Watch Video

Mugilraj LinkedIn: https://www.linkedin.com/in/mugilrajsekar/Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman discusses the health benefits of Muscadine grapes with Dr. Stephen Talcott, a PhD chemist and professor of Food Chemistry at Texas A&M. The conversation delves into the unique biochemical properties of Muscadine grapes, their polyphenol content, and their potential health benefits compared to other fruits like Acai and common grapes. They also explore the bioavailability of nutrients, the role of phytoalexins, and the benefits of Muscadine grape-derived products. Dr. Talcott shares his insights on ongoing research at Wake Forest University, the advantages of Muscadine grape products for chemotherapy patients, and the benefits of using these products as natural health supplements. The episode highlights various Muscadine grape products available from Mighty Muscadine and Vinetastic, including juices, supplements, and topical applications, and offers a special discount code for listeners.

Dr. Hoffman continues his conversation with Stephen T. Talcott, Ph.D., Professor of Food Chemistry, Department of Food Science and Technology at Texas A&M University, about the powerful health benefits of the muscadine grape.

Episode Title: Episode #63, Wearables: the Good, Bad, and Ugly, with Don Matutina, MS Don's Bio: Don Matutina, MS, is a research scientist and health professional with a multifaceted background in dietetics, exercise physiology, and culinary arts. He earned his BS in Dietetics and MS in Nutrition from the University of Kentucky and holds a culinary arts certificate (Certified Culinarian). Don is a Level 1 Sommelier with advanced training and has served as a research coordinator on multiple clinical trials, specializing in exercise physiology and wearable technology. His expertise bridges science, nutrition, and practical lifestyle interventions, providing unique insight into the applications and pitfalls of modern wearable devices. Description: In this episode of the Elevate Yourself podcast, Rob sits down with Don Matutina, MS, to explore the rapidly evolving world of wearable technology. Don breaks down the “good, bad, and ugly” of wearables, helping listeners understand what these devices can really measure, their limitations, and the potential unintended consequences of tracking every step, heart beat, and calorie burned. Listeners will learn the differences between consumer wearables and research-grade devices, insights from clinical trials Don has coordinated, and the ways wearables can enhance—or sometimes complicate—our health and fitness journeys. Don also shares his perspective on privacy, AI, and emerging technology concerns in the wearable space, offering practical guidance for anyone looking to integrate these tools into their daily routine. Topics Covered: Don's Background and Expertise Learn about Don's journey from dietetics and culinary arts to exercise physiology and clinical research, including his work as a research coordinator on multiple trials and his unique blend of science, nutrition, and lifestyle experience. Understanding Wearables Don defines what constitutes a wearable device, explains how most people use them, and contrasts consumer wearables with research-grade devices. Clinical Trials and Insights Explore Don's experience using wearables in research studies, including which devices were used, what metrics were tracked, and the key findings that emerged. The Good, Bad, and Ugly of Wearables Learn about the benefits of wearables, potential unintended consequences, and challenges related to accuracy, privacy, and AI integration. Rapid Fire – “One Thing” Don shares practical and personal insights on what elevates his science and life, from daily habits to recent accomplishments. Learn More: Don Matutina research article on exercise Athletic Brewing: athleticbrewing.com – Use code ELEVATE30 for 30% off your first online order.

Send us a textDr. Michael Koren is joined by Dr. Ezekiel "Zeke" Emanuel, an oncologist, bioethicist, and former White House advisor. Dr. Emanuel talks about his enduring interest in bioethics and the importance of ethics in areas like clinical research. The two doctors also talk about shared experiences at Harvard Medical School and Dr. Emanuel's contributions to bioethics in healthcare and research over his career. They close Part 1 of this conversation with Dr. Emanuel laying out the disparities between US healthcare spending and health outcomes.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

View the Show Notes For This Episode Dr. Andrea McBeth discusses how Stool-derived Postbiotics can restore gut health with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights   In this episode of the Rational Wellness Podcast, host Dr. Ben White discusses postbiotics with Dr. Andrea McBeth, a naturopathic clinician and expert in functional gastroenterology and the microbiome. Dr. McBeth shares insights into her work with fecal microbial transplants and her development of the pheno-biotic supplement made from sterilized fecal matter. The conversation dives into the benefits of postbiotics for various gastrointestinal conditions and overall gut health, the complexities of bile acids and their roles in the body, and the emerging understanding of the microbiome's impact on brain and immune function. Dr. McBeth also highlights the stringent criteria for selecting stool donors for her supplements and announces an innovative partnership for clinical trials to gather more data on the effectiveness of postbiotics.     00:29 Meet Dr. Andrea Macbeth: Expert in Functional Gastroenterology 01:26 The Science and Benefits of Fecal Microbial Transplants 04:50 Exploring Bile Acids and Their Clinical Importance 10:02 Understanding Prebiotics, Probiotics, and Postbiotics 12:28 The Development and Benefits of Sterilized Postbiotic Products 14:36 The Apollo Wearable: Managing Stress and Improving Sleep 16:07 How Postbiotics Enhance Gut Health and Overall Wellbeing 28:01 The Role of the Microbiome in Immune Education 29:02 Postbiotics and Their Complementary Role 31:51 Clinical Trials and Data Collection 32:58 Dosage Recommendations and Usage 35:52 Probiotics vs. Fecal Microbiota Transplantation (FMT) 42:20 Misconceptions About the Gut Microbiome 48:19 Sourcing and Criteria for Donor Stool 50:04 Conclusion and Final Thoughts       ___________________________________________________________________ Dr. Andrea McBeth is the founder and CEO of Thaena, a pioneering microbiome therapeutics company. She has a Bachelor's in Biochemistry, focusing on molecular biology, and a Doctorate in Naturopathic Medicine. Early in her career, Andrea directed her ND clinical practice toward functional GI disorders and autoimmunity, launching one of the first stool banks for fecal microbiota transplantation to treat Clostridioides difficile infections.  Driven by the interface between gut microbes and human health, Andrea invented ThaenaBiotic, the first human-derived postbiotic supplement. The website is Thaena.com. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

Clinical trials are vital to offering and developing the most effective treatment options. However, there are large disparities in enrollment across race, ethnicity, geography, and type of cancer care center. Mary Bird Perkins Cancer Center in Baton Rouge, LA uses local partnerships, culturally tailored outreach, and workforce innovation to drive sustainable and equitable participation in clinical trials. Minorities now make up 21% of their clinical trial participation, surpassing the national average. Following these meaningful gains in attracting local minority populations and underserved communities to take part in clinical trials, the Mary Bird Perkins research team received a grant to further support this work. In this episode of CANCER BUZZ, Victor Lin, MD, PhD, research medical director at Mary Bird Perkins Cancer Center, shares strategies for success in their community, including awareness campaigns and partnerships. CANCER BUZZ also speaks with TaeJeanne “TJ” Taylor-Lawrence, RN, registered nurse and patient navigator, about building relationships and supporting patients in clinical trials.     “We really, really have to be thinking, from a trial design standpoint, about the barriers that we're throwing up in the name of trying to keep the science and the data clean.” - Victor Lin, MD, PhD    “There's been this long-standing perception that cancer clinical trials are really the domain of only academic cancer centers. But I think increasingly we're finding that ... community cancer centers can be more nimble and are perfectly capable of running the same trials and seeing these patients where they live.” - Victor Lin, MD, PhD    “I think that representation builds trust. If people don't see themselves in this process, whether it's in the data, whether it's in the staff, or any of the outreach programs that we have, they're just less likely to believe that this is for them. In my community, black and brown communities especially, I think there's a deep need to feel seen, respected, and understood. When a patient sees someone that looks like them or shares their background talking about clinical trials, I think that that shifts the energy.” - TaeJeanne “TJ” Taylor-Lawrence, RN    “If the research does not reflect all of us, the solutions won't either.” - TaeJeanne “TJ” Taylor-Lawrence, RN    Victor Lin, MD, PhD Research Medical Director Mary Bird Perkins Cancer Center Baton Rouge, LA   TaeJeanne “TJ” Taylor-Lawrence, RN Registered Nurse Mary Bird Perkins Cancer Center Baton Rouge, LA   Resources: ACCC Community Oncology Research Institute (ACORI) Bringing Cancer Research to the Community:  Strategic Approaches to Representative Oncology Clinical Trial Design Mary Bird Perkins Cancer Center Receives $400,000 Grant to Continue Expansion of Nationally-Recognized Clinical Trials Program

In this episode of WCG Talks Trials, Cristin MacDonald, Doug Mayer, and Tyler Bye discuss how Software as a Service (SaaS) solutions are democratizing the clinical trial landscape. Learn how SaaS platforms are enabling organizations of all sizes to leverage cutting-edge technology, improving collaboration, standardization, and data security throughout the clinical research process. The team shares the benefits of adopting SaaS, practical insights for successful implementation, and highlights the pivotal role of technology partnerships in supporting innovation and research efficiency. Tune in to discover how your organization can optimize clinical trials and accelerate research impact with SaaS technology.

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Professor Vijay Kunadian from the University of Newcastle and Sarah Brown, a patient with heart disease, who are both co-authors on a consensus statement. They discuss the state of research participation among females in each area of cardiovascular disease, identify barriers to research for females in each area, and finally, describe strategies to increase female involvement in cardiovascular research. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us reach more people - thank you! Link to published paper: Paper - https://heart.bmj.com/content/early/2025/05/28/heartjnl-2024-325545 Editorial - https://heart.bmj.com/content/early/2025/05/28/heartjnl-2025-325979

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

In this episode I discuss clinical trial simulations. I review concepts of trial simulation including different variability terms and when to use them. I also share my thoughts on 3 different applications used in clinical trial simulation. Links discussed in the show:Trial Simulator Software page Simulx Software page You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Send us a textDr. Michael Koren joins Kevin Geddings to wax nostalgic about the past generation and what has changed for the better and for the worse. They note that there have been improvements in areas like food, but that air travel and the healthcare experience have deteriorated precipitously. They then contrast this with the massive improvements in the clinical research experience, where around 97-99% of participants say they would do another study. Tune in to find out why this is the case with Dr. Koren and Kevin Geddings.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textAssociation of patent ductus arteriosus treatment in extremely low gestational age neonates with two year kidney outcomes: a secondary analysis of the preterm erythropoietin neuroprotection trial (PENUT).Condit PE, Guillet R, Kaluarachchi D, Griffin RL, Menon S, Askenazi DJ, Harer MW.BMC Nephrol. 2025 Mar 19;26(1):138. doi: 10.1186/s12882-025-04065-8.PMID: 40108500 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Unlocking Innovation: The Alzheimer's Insights AI Prize and Its Impact on Healthcare There are currently more than 55 million people worldwide living with Alzheimer's disease and related dementias. Recent breakthroughs in new treatments and diagnostics provide hope, but there is potential to accelerate the pace of discovery and development. Last year, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) and Gates Ventures, the private office of Bill Gates, launched the Alzheimer's Moonshot. This initiative breaks down silos and fosters meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. Now, the Alzheimer's Disease Data Initiative (AD Data Initiative) is backing visionary AI solutions to accelerate Alzheimer's research with the launch of a new million-dollar prize competition. The goal is to leverage agentic AI – AI that can plan, reason, and act autonomously – to help drive breakthroughs in  Alzheimer's disease and related dementias research. Gregory Moore, MD, PhD, senior advisor to Gates Ventures and the Alzheimer's Disease Data Initiative, sat down with us to share how you can join the competition to harness AI to radically accelerate Alzheimer's disease research. The Alzheimer's Insights AI Prize offers $1M to the winner for the agentic AI solution that can generate a powerful leap in the pace, scale, and reach of ADRD research. Drawing from his unique background in both engineering and medicine, Dr. Moore discusses how AI could dramatically accelerate drug discovery and clinical trials by up to 50%. The initiative aims to break down traditional research barriers by harmonizing diverse data sets, from genomics to neuroimaging, making breakthroughs more accessible to the global scientific community. The Alzheimer's Insights AI Prize competition semi-finalist teams will be selected to present at a pitch event alongside the Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego this December, where innovators worldwide will present their ideas to a distinguished panel of judges from tech, academia, and venture capital. From there, up to three finalist teams will be invited to a final event at the AD/PD International Conference next March in Copenhagen, Denmark. With travel support available for participants, this initiative ensures global accessibility and collaboration. Ready to learn how AI could revolutionize brain health research to potentially detect Alzheimer's earlier, improve treatments, and work toward prevention and cures? Listen to this inspiring episode that bridges technology and medicine in the fight against dementia. Then visit Alzheimer's Insights AI Prize to learn more and apply by September 12, 2025.     Do you want to participate in live conversations with industry luminaries? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Fireside Chats, Expert Office Hours, and Peer Circles are benefits of our Health Moonshot Community Membership. To get involved, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

In this Editor's Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.